1. Key Insights 2. Executive Summary of B-cell NHL 3. SWOT Analysis for B-cell NHL 4. B-cell NHL: Patient Share of B-cell NHL at a Glance 4.1. Total Patient Share (%) Distribution in B-cell NHL First-line Therapies in 2017 4.2. Total Patient Share (%) Distribution in B-cell NHL First-line Therapies in 2028 4.3. Total Patient Share (%) Distribution in Relapsed/Refractory B-cell NHL in 2017 4.4. Total Patient Share (%) Distribution in Relapsed/Refractory B-cell NHL in 2028 5. B-cell NHLs: Market Overview at a Glance 5.1. Total Market Share (%) Distribution of B-cell NHL in 2017 5.2. Total Market Share (%) Distribution of B-cell NHL in 2028 6. B-cell Non-Hodgkin Lymphoma (NHL): Disease Background and Overview 6.1. Types of B-cell NHL 6.1.1. Diffuse large B-cell lymphoma (DLBCL) 6.1.2. Burkitt Lymphoma (BL) 6.1.3. Mantle Cell Lymphoma (MCL) 6.1.4. Follicular Lymphoma (FL) 6.1.5. Marginal Zone Lymphoma (MZL) 6.1.6. Chronic Lymphocytic Leukemia (CLL) and Small-Cell Lymphocytic Lymphoma (SLL) 6.2. Origin and Pathogenesis of B-cell NHL 6.2.1. Genetic Lesions in the Pathogenesis of B-cell Lymphomas 6.2.2. Microenvironmental Interactions in B-Cell Lymphomas and the Role of the BCR 6.3. Risk Factors for NHL 6.4. Staging for B-cell NHL 6.4.1. Staging of NHL in Adults 6.4.2. Staging of NHL in Children 6.4.3. Staging Systems for Chronic Lymphocytic Lymphoma (CLL) 6.5. Survival Rate for NHL (5-year) 6.6. Diagnosis of NHL 6.6.1. Diagnostic Algorithm for B-cell NHL 6.6.2. Evaluation 6.6.3. Testing Strategies to Diagnose B-cell Lymphomas 6.6.4. Stratification of High-Grade B-cell Lymphomas Using Laboratory Techniques 6.6.5. Summary of Recommendations for Diagnosis and pathology/molecular biology (DLBCL): European Society for Medical Oncology (ESMO) 7. Epidemiology and Patient Population 7.1. Epidemiology Key Findings 7.2. Assumptions and Rationale: 7MM 8. Epidemiology Scenario: 7MM 8.1. Total Incidence of NHL in the 7MM 8.1.1. Total Incidence cases of B cell-NHL in the 7MM 8.1.2. Gender-specific Incidence of B-cell NHL in the 7MM 8.1.3. Age-specific Incidence of B-cell NHL in the 7MM 8.1.4. Subtype - Specific Incidence of B-cell NHL in the 7MM 8.1.5. Stage-Specific Incidence of B-cell NHL in the 7MM 9. United States Epidemiology 9.1. Total Incidence cases of B cell-NHL in the United States 9.2. Age-specific Incidence of B-cell NHL in the United States 9.3. Subtype-Specific Incidence of B-cell NHL in the United States 9.4. Stage-Specific Incidence of B-cell NHL in the United States 10. EU-5 Country-wise Epidemiology 10.1. Germany Epidemiology 10.1.1. Total Incidence cases of B cell-NHL in Germany 10.1.2. Age-specific Incidence of B-cell NHL in Germany 10.1.3. Subtype-Specific Incidence of B-cell NHL in Germany 10.1.4. Stage-Specific Incidence of B-cell NHL in Germany 10.2. France Epidemiology 10.2.1. Total Incidence cases of B cell-NHL in France 10.2.2. Age-specific Incidence of B-cell NHL in France 10.2.3. Subtype-Specific Incidence of B-cell NHL in France 10.2.4. Stage-Specific Incidence of B-cell NHL in France 10.3. Italy Epidemiology 10.3.1. Total Incidence cases of B cell-NHL in Italy 10.3.2. Age-specific Incidence of B-cell NHL in Italy 10.3.3. Subtype-Specific Incidence of B-cell NHL in Italy 10.3.4. Stage-Specific Incidence of B-cell NHL in Italy 10.4. Spain Epidemiology 10.4.1. Total Incidence cases of B cell-NHL in Spain 10.4.2. Age-specific Incidence of B-cell NHL in Spain 10.4.3. Subtype-Specific Incidence of B-cell NHL in Spain 10.4.4. Stage-Specific Incidence of B-cell NHL in Spain 10.5. United Kingdom Epidemiology 10.5.1. Total Incidence cases of B cell-NHL in the United Kingdom 10.5.2. Age-specific Incidence of B-cell NHL in the United Kingdom 10.5.3. Subtype-Specific Incidence of B-cell NHL in the United Kingdom 10.5.4. Stage-Specific Incidence of B-cell NHL in the United Kingdom 11. Japan Epidemiology 11.1. Total Incidence cases of B cell-NHL in Japan 11.2. Age-specific Incidence of B-cell NHL in Japan 11.3. Subtype-Specific Incidence of B-cell NHL in Japan 11.4. Stage-Specific Incidence of B-cell NHL in Japan 12. Current Treatment Practices for B-cell NHL: As per Leukemia & Lymphoma Society (LLS) 12.1. Treatment Overview 12.1.1. Factors That Influence Treatment 12.1.2. The International Prognostic Index (IPI) 12.1.3. Treatment Considerations for Children, Adolescents, and Young Adults 12.2. Treatment of B-cell NHL Subtypes 12.2.1. Diffuse Large B-Cell Lymphoma (DLBCL) 12.2.2. Burkitt Lymphoma 12.2.3. Mantle Cell Lymphoma (MCL) 12.2.4. Follicular Lymphoma (FL) 12.2.5. Marginal Zone Lymphoma (MZL) 12.2.6. Small-Cell Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukemia (CLL) 13. Unmet Needs 14. Marketed Products 14.1. Brukinsa (Zanubrutinib): BeiGene 14.1.1. Product Description 14.1.2. Regulatory Milestones 14.1.3. Other Developmental Activities 14.1.4. Pivotal Clinical Trials 14.1.5. Ongoing Clinical Trials 14.2. Polivy (Polatuzumab vedotin): Hoffmann-La Roche 14.2.1. Product Description 14.2.2. Regulatory Milestones 14.2.3. Other Developmental Activities 14.2.4. Pivotal Clinical Trials 14.2.5. Ongoing Current Pipeline Activity 14.3. Venetoclax (ABT199): AbbVie and Roche 14.3.1. Product Description 14.3.2. Regulatory Milestones 14.3.3. Other Developmental Activities 14.3.4. Pivotal Clinical Trials 14.3.5. Ongoing Clinical Trials 14.4. Kymriah (tisagenlecleucel): Novartis 14.4.1. Product Description 14.4.2. Regulatory Milestones 14.4.3. Other Developmental Activities 14.4.4. Pivotal Clinical Trials 14.4.5. Ongoing Current Pipeline Activity 14.5. Copiktra (Duvelisib): Verastem 14.5.1. Product Description 14.5.2. Regulatory Milestones 14.5.3. Other Developmental Activities 14.5.4. Pivotal Clinical Trials 14.6. Keytruda (Pembrolizumab): Merck Sharp & Dohme 14.6.1. Product Description 14.6.2. Regulatory Milestones 14.6.3. Pivotal Clinical Trials 14.6.4. Ongoing Current Pipeline Activity 14.7. Yescarta (Axicabtagene ciloleucel; KTE-C19): Gilead Sciences 14.7.1. Product Description 14.7.2. Regulatory Milestones 14.7.3. Other Developmental Activities 14.7.4. Pivotal Clinical Trials 14.7.5. Ongoing Current Pipeline Activity 14.8. Aliqopa (Copanlisib; BAY 80-6946): Bayer 14.8.1. Product Description 14.8.2. Regulatory Milestones 14.8.3. Other Developmental Activities 14.8.4. Pivotal Clinical Trials 14.8.5. Ongoing Current Pipeline Activity 14.9. Calquence (Acalabrutinib): AstraZeneca 14.9.1. Product Description 14.9.2. Regulatory Milestones 14.9.3. Other Dvelopmental Activities 14.9.4. Pivotal Clinical Trials 14.9.5. Ongoing Clinical Trials 14.10. Imbruvica (Ibrutinib): Janssen/Pharmacyclics (AbbVie Company) 14.10.1. Product Description 14.10.2. Regulatory Milestones 14.10.3. Other Developmental Activities 14.10.4. Pivotal Clinical Trials 14.10.5. Ongoing Current Pipeline Activity 14.11. Zydelig (Idelalisib): Gilead Sciences 14.11.1. Product Description 14.11.2. Regulatory Milestones 14.11.3. Other Developmental Activities 14.11.4. Pivotal Clinical Trials 14.11.5. Ongoing Current Pipeline Activity 14.12. Gazyva (Obinutuzumab, GA-101): Genentech (Roche Group) 14.12.1. Product Description 14.12.2. Regulatory Milestones 14.12.3. Other Developmental Activities 14.12.4. Pivotal Clinical Trials 14.12.5. Ongoing Current Pipeline Activity 14.13. Revlimid (lenalidomide): Celgene Corporation 14.13.1. Product Description 14.13.2. Regulatory Milestones 14.13.3. Other Developmental Activities 14.13.4. Pivotal Clinical Trials 14.13.5. Ongoing Clinical Trials 14.14. Velcade (bortezomib): Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutical 14.14.1. Product Description 14.14.2. Regulatory Milestones 14.14.3. Other Developmental Activities 14.14.4. Pivotal Clinical Trials 14.14.5. Ongoing Current Pipeline Activity 14.15. Zevalin (ibritumomab tiuxetan): Spectrum Pharmaceuticals 14.15.1. Product Description 14.15.2. Regulatory Milestones 14.15.3. Other Developmental Activities 14.15.4. Pivotal Clinical Trials 14.16. Torisel: Pfizer 14.16.1. Product Description 14.16.2. Regulatory Milestones 14.16.3. Pivotal Clinical Trials 15. Emerging Therapies 15.1. Key Cross 15.2. Tafasitamab (MOR208; formerly XmAb 5574): MorphoSys AG 15.2.1. Product Description 15.2.2. Other Developmental Activities 15.2.3. Clinical Development 15.2.4. Safety and Efficacy 15.3. Lisocabtagene maraleucel (JCAR017): Bristol-Myers Squibb 15.3.1. Product Description 15.3.2. Other Developmental Activities 15.3.3. Clinical Development 15.3.4. Safety and Efficacy 15.4. Enzastaurin Hydrochloride (DB102): Denovo Biopharma 15.4.1. Product Description 15.4.2. Other Developmental Activities 15.4.3. Clinical Development 15.4.4. Safety and Efficacy 15.5. Avelumab (Bavencio): Pfizer/Merck 15.5.1. Product Description 15.5.2. Other Developmental Activities 15.5.3. Clinical Development 15.6. Umbralisib (TG-1202): TG Therapeutics 15.6.1. Product Description 15.6.2. Other Developmental Activities 15.6.3. Clinical Development 15.6.4. Safety and Efficacy 16. B-cell NHL: Seven Major Market Analysis 16.1. Key Findings 16.2. Total Market Size of B-cell NHL in the 7MM 16.3. Market Size of B-cell NHL by Therapeutic Class in the 7MM 17. Market Outlook: 7MM 18. United States Market Size 18.1. Total Market size of B-cell NHL in the United States 18.2. Market Size of B-cell NHL by Line of Therapies in the US 19. EU-5 Market Size 19.1. Germany Market Size 19.1.1. Total Market size of B-cell NHL in Germany 19.1.2. Market Size of B-cell NHL by Line of Therapies in Germany 19.2. France Market Size 19.2.1. Total Market size of B-cell NHL in France 19.2.2. Market Size of B-cell NHL by Therapies in France 19.3. Italy Market Size 19.3.1. Total Market size of B-cell NHL in Italy 19.3.2. Market Size of B-cell NHL by Line of Therapies in Italy 19.4. Spain Market Size 19.4.1. Total Market size of B-cell NHL in Spain 19.4.2. Market Size of B-cell NHL by Line of Therapies in Spain 19.5. United Kingdom Market Size 19.5.1. Total Market size of B-cell NHL in the United Kingdom 19.5.2. Market Size of B-cell NHL by Line of Therapies in the United Kingdom 20. Japan Market Size 20.1. Total Market size of B-cell NHL in Japan 20.2. Market Size of B-cell NHL by Therapies in Japan 21. Market Access and Reimbursement Scenario of B-cell NHL Therapies 21.1. CAR-T cell Therapies 22. Market Drivers 23. Market Barriers 24. Appendix 24.1. Bibliography 24.2. Report Methodology 25. Disclaimer 26. DelveInsight Capabilities 27. About DelveInsight

Table 1 Summary of B-cell NHL Market, Epidemiology, and Key Events (2017–2028) Table 2 Stage-wise Survival Rate of DLBCL Table 3 Stage wise Survival Rate of FL Table 4 Stage wise Survival Rate of MZL Table 5 Genetic Lesions in Human B-cell Lymphomas Table 6 Rai Staging System Table 7 Binet Staging System Table 8 Major Sources Used Table 9 Total Incidence of NHL in the 7MM (2017–2028) Table 10 Total Incidence cases of B cell-NHL in the 7MM (2017–2028) Table 11 Gender-specific Incidence of B-cell NHL in the 7MM (2017–2028) Table 12 Age-specific Incidence of B-cell NHL in the 7MM (2017–2028) Table 13 Subtype - Specific Incidence of B-cell NHL in the 7MM (2017–2028) Table 14 Stage-Specific Incidence of B-cell NHL in the 7MM (2017–2028) Table 15 Total Incidence cases of B cell-NHL in the United States (2017–2028) Table 16 Age-specific Incidence of B-cell NHL in the United States (2017–2028) Table 17 Subtype - Specific Incidence of B-cell NHL in the United States (2017–2028) Table 18 Stage-Specific Incidence of B-cell NHL in the United States (2017–2028) Table 19 Total Incidence cases of B cell-NHL in Germany (2017–2028) Table 20 Age-specific Incidence of B-cell NHL in Germany (2017–2028) Table 21 Subtype - Specific Incidence of B-cell NHL in Germany (2017–2028) Table 22 Stage-Specific Incidence of B-cell NHL in Germany (2017–2028) Table 23 Total Incidence cases of B cell-NHL in France (2017–2028) Table 24 Age-specific Incidence of B-cell NHL in France (2017–2028) Table 25 Subtype - Specific Incidence of B-cell NHL in France (2017–2028) Table 26 Stage-Specific Incidence of B-cell NHL in France (2017–2028) Table 27 Total Incidence cases of B cell-NHL in Italy (2017–2028) Table 28 Age-specific Incidence of B-cell NHL in Italy (2017–2028) Table 29 Subtype - Specific Incidence of B-cell NHL in Italy (2017–2028) Table 30 Stage-Specific Incidence of B-cell NHL in Italy (2017–2028) Table 31 Total Incidence cases of B cell-NHL in Spain (2017–2028) Table 32 Age-specific Incidence of B-cell NHL in Spain (2017–2028) Table 33 Subtype - Specific Incidence of B-cell NHL in Spain (2017–2028) Table 34 Stage-Specific Incidence of B-cell NHL in Spain (2017–2028) Table 35 Total Incidence cases of B cell-NHL in the United Kingdom ( (2017–2028) Table 36 Age-specific Incidence of B-cell NHL in the United Kingdom (2017–2028) Table 37 Subtype - Specific Incidence of B-cell NHL in the United Kingdom (2017–2028) Table 38 Stage-Specific Incidence of B-cell NHL in the United Kingdom (2017–2028) Table 39 Total Incidence cases of B cell-NHL in Japan (2017–2028) Table 40 Age-specific Incidence of B-cell NHL in Japan (2017–2028) Table 41 Subtype - Specific Incidence of B-cell NHL in Japan (2017–2028) Table 42 Stage-Specific Incidence of B-cell NHL in Japan (2017–2028) Table 43 Polivy, Clinical Trial Description, 2019 Table 44 Keytruda, Clinical Trial Description, 2019 Table 45 Gazyva, Clinical Trial Description, 2019 Table 46 Yescarta, Clinical Trial Description, 2019 Table 47 Aliqopa, Clinical Trial Description, 2019 Table 48 Ibrutinib, Clinical Trial Description, 2019 Table 49 Imbruvica, Clinical Trial Description, 2019 Table 50 Imbruvica, Clinical Trial Description, 2019 Table 51 Imbruvica, Clinical Trial Description, 2019 Table 52 Zydelig, Clinical Trial Description, 2019 Table 53 Gazyva, Clinical Trial Description, 2019 Table 54 Gazyva, Clinical Trial Description, 2019 Table 55 Velcade, Clinical Trial Description, 2019 Table 56 Emerging Drugs Key cross Competition Table 57 Tafasitamab, Clinical Trial Description, 2019 Table 58 JCAR017, Clinical Trial Description, 2019 Table 59 Enzastaurin Hydrochloride (DB102) , Clinical Trial Description, 2019 Table 60 Avelumab , Clinical Trial Description, 2019 Table 61 Umbralisib (TGR-1202), Clinical Trial Description, 2019 Table 62 7MM Market Size of B-cell NHL in USD Million (2017–2028) Table 63 7MM Market Size of B-cell NHL By Class in USD Million (2017–2028) Table 64 List of Few Marketed Products with their respective Therapeutic Classes Table 65 US Market Size of B-cell NHL By Class in USD Million (2017–2028) Table 66 US Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028) Table 67 US Market Size of B-cell NHL of Relapsed/ Refractory in USD Million (2017–2028) Table 68 Germany Market Size of B-cell NHL By Class in USD Million (2017–2028) Table 69 Germany Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028) Table 70 Germany Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028) Table 71 France Market Size of B-cell NHL By Class in USD Million (2017–2028) Table 72 France Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028) Table 73 France Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028) Table 74 Italy Market Size of B-cell NHL By Class in USD Million (2017–2028) Table 75 Italy Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028) Table 76 Italy Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028) Table 77 Spain Market Size of B-cell NHL By Class in USD Million (2017–2028) Table 78 Spain Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028) Table 79 Spain Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028) Table 80 United Kingdom Market Size of B-cell NHL By Class in USD Million (2017–2028) Table 81 United Kingdom Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028) Table 82 United Kingdom Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028) Table 83 Japan Market Size of B-cell NHL By Class in USD Million (2017–2028) Table 84 Japan Market Size of B-cell NHL By First-line Of Therapy in USD Million (2017–2028) Table 85 Japan Market Size of B-cell NHL By Relapsed/ refractory USD Million (2017–2028) Table 86 HTA Assessment in the EU-5 Countries Figure 1 B-cell NHL SWOT Analysis Figure 2 B-cell Development Figure 3 Germinal Center Reaction and Cellular Origin of Human B-cell Lymphomas Figure 4 Location of Non-Hodgkin Lymphoma in the Body for Stage 1 Figure 5 Location of Non-Hodgkin Lymphoma in the Body for Stage 2 Figure 6 Location of Non-Hodgkin Lymphoma in the Body for Stage 3 Figure 7 Location of Non-Hodgkin Lymphoma in the Body for Stage 4 Figure 8 Survival Rate for NHL Figure 9 NHL 5-Year Relative Survival by Stage at Diagnosis Figure 10 Diagnostic Algorithm for Major B-cell Lymphomas Figure 11 Additional Tests for NHL Figure 12 Global Heat Map of NHL Figure 13 Total Incidence of NHL in the 7MM (2017–2028) Figure 14 Total Incidence cases of B cell-NHL in the 7MM (2017–2028) Figure 15 Gender-specific Incidence of B-cell NHL in the 7MM (2017–2028) Figure 16 Age-specific Incidence of B-cell NHL in the 7MM (2017–2028) Figure 17 Subtype - Specific Incidence of B-cell NHL in the 7MM (2017–2028) Figure 18 Stage-Specific Incidence of B-cell NHL in the 7MM (2017–2028) Figure 19 Total Incidence cases of B cell-NHL in the United States (2017–2028) Figure 20 Age-specific Incidence of B-cell NHL in the United States (2017–2028) Figure 21 Subtype - Specific Incidence of B-cell NHL in the United States (2017–2028) Figure 22 Stage-Specific Incidence of B-cell NHL in the United States (2017–2028) Figure 23 Total Incidence cases of B cell-NHL in Germany (2017–2028) Figure 24 Age-specific Incidence of B-cell NHL in Germany (2017–2028) Figure 25 Subtype - Specific Incidence of B-cell NHL in Germany (2017–2028) Figure 26 Stage-Specific Incidence of B-cell NHL in Germany (2017–2028) Figure 27 Total Incidence cases of B cell-NHL in France (2017–2028) Figure 28 Age-specific Incidence of B-cell NHL in France (2017–2028) Figure 29 Subtype - Specific Incidence of B-cell NHL in France (2017–2028) Figure 30 Stage-Specific Incidence of B-cell NHL in France (2017–2028) Figure 31 Total Incidence cases of B cell-NHL in Italy (2017–2028) Figure 32 Age-specific Incidence of B-cell NHL in Italy (2017–2028) Figure 33 Subtype - Specific Incidence of B-cell NHL in Italy (2017–2028) Figure 34 Stage-Specific Incidence of B-cell NHL in Italy (2017–2028) Figure 35 Total Incidence cases of B cell-NHL in Spain (2017–2028) Figure 36 Age-specific Incidence of B-cell NHL in Spain (2017–2028) Figure 37 Subtype - Specific Incidence of B-cell NHL in Spain (2017–2028) Figure 38 Stage-Specific Incidence of B-cell NHL in Spain (2017–2028) Figure 39 Total Incidence cases of B cell-NHL in the United Kingdom (2017–2028) Figure 40 Age-specific Incidence of B-cell NHL in the United Kingdom (2017–2028) Figure 41 Subtype - Specific Incidence of B-cell NHL in the United Kingdom (2017–2028) Figure 42 Stage-Specific Incidence of B-cell NHL in the United Kingdom (2017–2028) Figure 43 Total Incidence cases of B cell-NHL in Japan (2017–2028) Figure 44 Age-specific Incidence of B-cell NHL in Japan (2017–2028) Figure 45 Subtype - Specific Incidence of B-cell NHL in Japan (2017–2028) Figure 46 Stage-Specific Incidence of B-cell NHL in Japan (2017–2028) Figure 47 First Line Therapy Algorithm for DLBCL (Spanish Lymphoma Group (GELTAMO) Guidelines) Figure 48 Treatment Algorithm for Patients with CLL/SLL Figure 49 Unmet Needs of B-cell NHL Figure 50 Market Size of B-cell NHL in the 7MM Countries in USD Million (2017–2028) Figure 51 Market Size of B-cell NHL by therapies in the 7MM, in USD Million (2017–2028) Figure 52 Market Size of B-cell NHL in the US, USD Millions (2017–2028) Figure 53 Market Size of B-cell NHL By First-line Of Therapy in the US, USD Millions (2017–2028) Figure 54 B-cell NHL By Relapsed and Refractory Market Size in the US, USD Millions (2017–2028) Figure 55 Market Size of B-cell NHL in Germany, USD Millions (2017–2028) Figure 56 Market Size of B-cell NHL By First-line Of Therapy in Germany, USD Millions (2017–2028) Figure 57 Market Size of B-cell NHL By Relapsed and Refractory in Germany, USD Millions (2017–2028) Figure 58 Market Size of B-cell NHL in France, USD Millions (2017–2028) Figure 59 Market Size of B-cell NHL by first line of therapy in France, USD Millions (2017–2028) Figure 60 B-cell NHL by Relapsed and Refractory Market Size, in France, USD Millions (2017–2028) Figure 61 Market Size of B-cell NHL in Italy, USD Millions (2017–2028) Figure 62 Market Size of B-cell NHL by first line of therapy in Italy, USD Millions (2017–2028) Figure 63 B-cell NHL by Relapsed and Refractory Market Size in Italy, USD Millions (2017–2028) Figure 64 Market Size of B-cell NHL in Spain, USD Millions (2017–2028) Figure 65 Market Size of B-cell NHL by First line of Therapy in Spain, USD Millions (2017–2028) Figure 66 B-cell NHL by Relapsed and Refractory Market Size in Spain, USD Millions (2017–2028) Figure 67 Market Size of B-cell NHL in the United Kingdom USD Millions (2017–2028) Figure 68 Market Size of B-cell NHL By First Line of Therapy in the United Kingdom in USD Millions (2017–2028) Figure 69 B-cell NHL by Relapsed and Refractory Market Size in the United Kingdom in USD Millions (2017–2028) Figure 70 Market Size of B-cell NHL in Japan, USD Millions (2017–2028) Figure 71 Market Size of B-cell NHL in Japan, USD Millions (2017–2028) Figure 72 B-cell NHL by Relapsed and Refractory Market Size in Japan in USD Millions (2017–2028) Figure 73 Market Drivers of B-cell NHL Figure 74 Market Barriers of B-cell NHL

1. Hoffmann-La Roche 2. Novartis 3. Gilead Sciences 4. Bristol-Myers Squibb 5. MorphoSys AG 6. Pfizer 7. Merck 8. AbbVie 9. Janssen 10. Bayer 11. AstraZeneca 12. Takeda 13. Epizyme 14. Xynomic Pharmaceuticals 15. Spectrum Pharmaceuticals